BACKGROUND:The purpose of this study was to determine the direct medical US cost of managing multiple sclerosis relapses.METHODS:Direct data analysis and cost modeling were employed to derive typical resource use profiles and costs in 2002 US dollars, from the perspective of a third-party payer responsible for comprehensive health-care. The location and scope of health care services provided over a 90-day period were used to define three levels of relapse management. Hospitalization and resulting subsequent care was defined as high intensity management. A medium level of intervention was defined as either use of the emergency room, an observational unit, or administration of acute treatments, such as intravenous methylprednisolone in an out...
A retrospective chart review indicated that 56 % of patients admitted to an acute-care hospital for ...
Background: Multiple Sclerosis (MS) is one of the most common diseases of the central nervous system...
Objective: To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the manageme...
JOURNAL ARTICLEBACKGROUND: Relapses can have a major impact on the lives of people with multiple scl...
Thesis (Master's)--University of Washington, 2015Background: Many new disease-modifying therapies (D...
Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sc...
Objective: In Portugal, the prevalence rate for multiple sclerosis (MS) has been estimated at 47 per...
Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sc...
AbstractObjectiveAlthough the global rate of multiple sclerosis (MS) is low, a few studies have docu...
Objective: To assess whether the introduction of the new diagnostic criteria and disease modifying t...
this study was to define the cost of multiple sclerosis (MS) from the per-spective of a managed care...
Background Disease modifying treatments (DMTs) are the main responsible for direct medical costs in ...
Multiple Sclerosis (MS) is a chronic and disabling disease characterized by demyelination of the cen...
ultiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurologi...
International audienceBackground: Studies have shown that oral high-dose methylprednisolone (MP) is ...
A retrospective chart review indicated that 56 % of patients admitted to an acute-care hospital for ...
Background: Multiple Sclerosis (MS) is one of the most common diseases of the central nervous system...
Objective: To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the manageme...
JOURNAL ARTICLEBACKGROUND: Relapses can have a major impact on the lives of people with multiple scl...
Thesis (Master's)--University of Washington, 2015Background: Many new disease-modifying therapies (D...
Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sc...
Objective: In Portugal, the prevalence rate for multiple sclerosis (MS) has been estimated at 47 per...
Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sc...
AbstractObjectiveAlthough the global rate of multiple sclerosis (MS) is low, a few studies have docu...
Objective: To assess whether the introduction of the new diagnostic criteria and disease modifying t...
this study was to define the cost of multiple sclerosis (MS) from the per-spective of a managed care...
Background Disease modifying treatments (DMTs) are the main responsible for direct medical costs in ...
Multiple Sclerosis (MS) is a chronic and disabling disease characterized by demyelination of the cen...
ultiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurologi...
International audienceBackground: Studies have shown that oral high-dose methylprednisolone (MP) is ...
A retrospective chart review indicated that 56 % of patients admitted to an acute-care hospital for ...
Background: Multiple Sclerosis (MS) is one of the most common diseases of the central nervous system...
Objective: To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the manageme...